- Total Funding
- $37.0M
- Last Round
- $37.0M Series CJul 2026
- Rounds
- 1
About
Cancer immunotherapy platform (formerly EG 427)
Summary
Cyllene Therapeutics is a Biotech company based in France. It has raised $37.0M in total across 1 round, most recently a $37.0M Series C round in Jul 2026.
Funding History
$37.0M
Jul 2026
Similar Companies
BeiGeneIPO
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Cambridge, United States10001+Biotech, Oncology
Corporate Round·$2.8B·Jan 2020
Avenzo
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
San Diego, United States1–10Biotech, Oncology
Series B·$832.0M·Sep 2025
Bicara TherapeuticsIPO
Clinical-stage biopharma developing dual-action biologics that combine targeted therapy and immun...
Cambridge, United States51–200Biotech, Healthcare
Series C·$586.0M·Dec 2023
BT
Bicycle TherapeuticsIPO
Novel bicyclic peptides and drug conjugates for cancer
Cambridge, United States201–500Biotech, Oncology
Private Equity·$555.0M·Jan 2024
Arcus BiosciencesIPO
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
Hayward, United States201–500Biotech, Healthcare
Corporate Round·$544.0M·Jan 2024
Tiantan Biological / China Biologic (泰邦生物集团)
China's leading blood products manufacturer
Beijing, China1001–5000Biotech, Healthcare
Growth Equity·$5.1B·Aug 2022